RADIOTHERAPY MARKET ANALYSIS

Key Developments

• On February 6, 2024, National Institutes of Health, announced that it had granted US$ 7.8 million to Washington University School of Medicine to support a radiation oncology center that is part of a select national network of centers aimed at understanding the biologic effects of radiation therapy in cancer treatment
• In May 2022, Elekta, a medical technology company, announced the launch of Elekta Esprit that offers significantly faster automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person
• In April 2022, Elekta, and GE Healthcare, a manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures, entered into a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
• In February 2022, the Department of Radiation Oncology at Max Institute of Cancer Care (MICC), Saket, India, launched the Radixact X9 Tomotherapy, which is combined with the second-generation synchronization respiratory motion management system. This radiation therapy treatment for cancer patients employs Artificial Intelligence (AI)-based real-time tracking and treatment delivery to ensure that the tumor is not missed due to chest or abdominal breathing movement during radiation.
• In June 2020, Accuray Incorporated, a medical technology company, announced that it had launched CyberKnife S7 System. CyberKnife S7 System is the next-generation CyberKnife platform, a robotic, non-invasive radiation therapy device capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders